[go: up one dir, main page]

AP2015008741A0 - Benzimidazolone derivatives as bromodomain inhibitors - Google Patents

Benzimidazolone derivatives as bromodomain inhibitors

Info

Publication number
AP2015008741A0
AP2015008741A0 AP2015008741A AP2015008741A AP2015008741A0 AP 2015008741 A0 AP2015008741 A0 AP 2015008741A0 AP 2015008741 A AP2015008741 A AP 2015008741A AP 2015008741 A AP2015008741 A AP 2015008741A AP 2015008741 A0 AP2015008741 A0 AP 2015008741A0
Authority
AP
ARIPO
Prior art keywords
bromodomain inhibitors
benzimidazolone derivatives
benzimidazolone
derivatives
bromodomain
Prior art date
Application number
AP2015008741A
Other languages
English (en)
Inventor
Jeff Zablocki
Hai Yang
David Sperandio
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2015008741A0 publication Critical patent/AP2015008741A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2015008741A 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors AP2015008741A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
AP2015008741A0 true AP2015008741A0 (en) 2015-09-30

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008741A AP2015008741A0 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Country Status (35)

Country Link
US (2) US20160031868A1 (xx)
EP (1) EP2978759B1 (xx)
JP (1) JP6339175B2 (xx)
KR (1) KR101847698B1 (xx)
CN (1) CN105102453B (xx)
AP (1) AP2015008741A0 (xx)
AU (1) AU2014241152B2 (xx)
BR (1) BR112015024078A2 (xx)
CA (1) CA2907502C (xx)
CL (1) CL2015002871A1 (xx)
CR (1) CR20150515A (xx)
CY (1) CY1119165T1 (xx)
DK (1) DK2978759T3 (xx)
EA (1) EA029497B1 (xx)
ES (1) ES2626397T3 (xx)
HR (1) HRP20170750T1 (xx)
HU (1) HUE034772T2 (xx)
IL (1) IL241186A0 (xx)
LT (1) LT2978759T (xx)
MD (1) MD4531C1 (xx)
MX (1) MX2015013798A (xx)
MY (1) MY176634A (xx)
NZ (1) NZ711586A (xx)
PE (1) PE20151982A1 (xx)
PH (1) PH12015502246A1 (xx)
PL (1) PL2978759T3 (xx)
PT (1) PT2978759T (xx)
RS (1) RS56050B1 (xx)
SG (1) SG11201507926RA (xx)
SI (1) SI2978759T1 (xx)
SM (1) SMT201700249T1 (xx)
TW (1) TWI530499B (xx)
UY (1) UY35516A (xx)
WO (1) WO2014160873A1 (xx)
ZA (1) ZA201506356B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2015004533A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016055028A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Therapeutic compounds and uses thereof
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
EP3397640B1 (en) 2015-12-29 2021-08-04 INSERM - Institut National de la Santé et de la Recherche Médicale Xanthine derivative inhibitors of bet proteins
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
WO2018097976A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
US11180510B2 (en) 2017-11-06 2021-11-23 Centre National De La Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
MX2020006612A (es) 2017-12-20 2020-11-09 Betta Pharmaceuticals Co Ltd Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
WO2020156017A1 (zh) * 2019-02-02 2020-08-06 石药集团中奇制药技术(石家庄)有限公司 靶向泛素化降解brd4蛋白化合物及其制备方法和应用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
EP4039333A4 (en) 2019-09-30 2024-02-14 Kyowa Kirin Co., Ltd. BET DEGRADATION AGENT
AU2021276673A1 (en) * 2020-05-21 2022-12-22 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117821344B (zh) * 2024-03-06 2024-07-26 江苏古道农业科技有限公司 一种草甘膦降解菌及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
PL3010503T3 (pl) * 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen

Also Published As

Publication number Publication date
PL2978759T3 (pl) 2017-08-31
CR20150515A (es) 2015-12-01
PE20151982A1 (es) 2016-01-28
PT2978759T (pt) 2017-05-31
HRP20170750T1 (hr) 2017-07-28
IL241186A0 (en) 2015-11-30
KR20150135476A (ko) 2015-12-02
KR101847698B1 (ko) 2018-04-10
CA2907502A1 (en) 2014-10-02
TW201504233A (zh) 2015-02-01
EA029497B1 (ru) 2018-04-30
AU2014241152A1 (en) 2015-09-17
MY176634A (en) 2020-08-19
UY35516A (es) 2014-09-30
ZA201506356B (en) 2017-08-30
NZ711586A (en) 2016-09-30
CN105102453B (zh) 2018-04-06
SI2978759T1 (sl) 2017-05-31
EA201591455A1 (ru) 2016-01-29
CY1119165T1 (el) 2018-02-14
PH12015502246A1 (en) 2016-02-01
WO2014160873A1 (en) 2014-10-02
JP2016515584A (ja) 2016-05-30
JP6339175B2 (ja) 2018-06-06
EP2978759A1 (en) 2016-02-03
MX2015013798A (es) 2016-02-16
CN105102453A (zh) 2015-11-25
US9255089B2 (en) 2016-02-09
AU2014241152B2 (en) 2016-11-03
SMT201700249T1 (it) 2017-07-18
RS56050B1 (sr) 2017-09-29
HK1220692A1 (en) 2017-05-12
MD4531C1 (ro) 2018-06-30
US20140296246A1 (en) 2014-10-02
MD20150104A2 (ro) 2016-02-29
LT2978759T (lt) 2017-05-25
CL2015002871A1 (es) 2016-05-13
EP2978759B1 (en) 2017-03-15
HUE034772T2 (en) 2018-02-28
DK2978759T3 (da) 2017-06-19
TWI530499B (zh) 2016-04-21
SG11201507926RA (en) 2015-10-29
US20160031868A1 (en) 2016-02-04
BR112015024078A2 (pt) 2017-07-18
MD4531B1 (ro) 2017-11-30
ES2626397T3 (es) 2017-07-24
CA2907502C (en) 2018-02-27

Similar Documents

Publication Publication Date Title
IL241186A0 (en) History of benzaimidazoles as bromodomain inhibitors
IL256946B (en) Bromodomain inhibitors
AP2015008869A0 (en) Benzimidazole derivatives as bromodomain inhibitors
IL243372A0 (en) bromine zone inhibitors
ZA201506575B (en) Dihydro-pyrrolopyridinone bromodomain inhibitors
IL240863B (en) Amatoxin derivatives
PL2953944T3 (pl) Pochodne pirydazynonowe-amidowe
IL244609B (en) History of 4-azaindole
LT3027598T (lt) Oksochinazolinil-butanamido dariniai
PT3087076T (pt) Derivados de imidazopirazinona